TABLE 2.
Descriptive statistics including clinicopathological features of all patients with nonmetastatic resected cardia gastric cancer stratified by treatment groups.
| Covariate | Statistics | Level | Treatment group |
Parametric p valuea | ||
|---|---|---|---|---|---|---|
| Perioperative chemotherapy (N = 369) | Postoperative chemoradiation (N = 1427) | Postoperative chemotherapy (N = 591) | ||||
| Age | N (Col %) | Below median | 224 (60.7) | 758 (53.12) | 283 (47.88) | <0.001 |
| N (Col %) | Above median | 145 (39.3) | 669 (46.88) | 308 (52.12) | ||
| Race | N (Col %) | White | 329 (89.16) | 1280 (89.7) | 528 (89.34) | 0.335 |
| N (Col %) | Black | 19 (5.15) | 85 (5.96) | 27 (4.57) | ||
| N (Col %) | Other | 21 (5.69) | 62 (4.34) | 36 (6.09) | ||
| Sex | N (Col %) | Male | 304 (82.38) | 1182 (82.83) | 466 (78.85) | 0.103 |
| N (Col %) | Female | 65 (17.62) | 245 (17.17) | 125 (21.15) | ||
| Median income quartiles 2008–2012 | N (Col %) | <$38 000 | 48 (13.01) | 188 (13.29) | 76 (12.88) | 0.969 |
| N (Col %) | $38 000–$47 999 | 93 (25.2) | 343 (24.24) | 155 (26.27) | ||
| N (Col %) | $48 000–$62 999 | 96 (26.02) | 391 (27.63) | 160 (27.12) | ||
| N (Col %) | ≥$63 000 | 132 (35.77) | 493 (34.84) | 199 (33.73) | ||
| Facility type | N (Col %) | Nonacademic/research program | 141 (39.39) | 856 (61.58) | 290 (49.83) | <0.001 |
| N (Col %) | Academic/research program | 217 (60.61) | 534 (38.42) | 292 (50.17) | ||
| Primary payor | N (Col %) | Private/not insured | 226 (61.25) | 755 (52.91) | 308 (52.12) | 0.009 |
| N (Col %) | Medicare/Medicaid/other government | 143 (38.75) | 672 (47.09) | 283 (47.88) | ||
| Charlson-Deyo score | N (Col %) | 0 | 287 (77.78) | 987 (69.17) | 391 (66.16) | <0.001 |
| N (Col %) | 1+ | 82 (22.22) | 440 (30.83) | 200 (33.84) | ||
| Year of diagnosis | N (Col %) | 2006–2010 | 136 (36.86) | 885 (62.02) | 339 (57.36) | <0.001 |
| N (Col %) | 2011–2016 | 233 (63.14) | 542 (37.98) | 252 (42.64) | ||
| Facility location | N (Col %) | Northeast | 133 (37.15) | 356 (25.61) | 191 (32.82) | <0.001 |
| N (Col %) | Midwest | 81 (22.63) | 379 (27.27) | 106 (18.21) | ||
| N (Col %) | West | 65 (18.16) | 208 (14.96) | 81 (13.92) | ||
| N (Col %) | South | 79 (22.07) | 447 (32.16) | 204 (35.05) | ||
| Grade | N (Col %) | Well/moderately differentiated | 129 (37.07) | 522 (38.05) | 194 (33.74) | 0.198 |
| N (Col %) | Poorly differentiated/undifferentiated | 219 (62.93) | 850 (61.95) | 381 (66.26) | ||
| Regional lymph nodes positive | N (Col %) | Negative | 130 (36.83) | 230 (17.46) | 93 (16.55) | <0.001 |
| N (Col %) | Positive | 223 (63.17) | 1087 (82.54) | 469 (83.45) | ||
| Clinical T | N (Col %) | 1–2 | 65 (21.31) | 405 (58.19) | 170 (54.49) | <0.001 |
| N (Col %) | 3 | 216 (70.82) | 272 (39.08) | 134 (42.95) | ||
| N (Col %) | 4 | 24 (7.87) | 19 (2.73) | 8 (2.56) | ||
| Clinical N | N (Col %) | 0 | 106 (32.02) | 627 (66.35) | 264 (64.55) | <0.001 |
| N (Col %) | 1 | 169 (51.06) | 223 (23.6) | 104 (25.43) | ||
| N (Col %) | 2–3 | 56 (16.92) | 95 (10.05) | 41 (10.02) | ||
| Pathologic T | N (Col %) | 0–2 | 90 (32.14) | 255 (28.27) | 93 (25.55) | 0.116 |
| N (Col %) | 3 | 169 (60.36) | 583 (64.63) | 232 (63.74) | ||
| N (Col %) | 4 | 21 (7.5) | 64 (7.1) | 39 (10.71) | ||
| Pathologic N | N (Col %) | 0 | 122 (38.98) | 215 (20.44) | 78 (17.93) | <0.001 |
| N (Col %) | 1 | 90 (28.75) | 479 (45.53) | 178 (40.92) | ||
| N (Col %) | 2 | 51 (16.29) | 228 (21.67) | 95 (21.84) | ||
| N (Col %) | 3 | 50 (15.97) | 130 (12.36) | 84 (19.31) | ||
| Surgical margins status | N (Col %) | Negative | 327 (90.58) | 1066 (77.58) | 484 (85.06) | <0.001 |
| N (Col %) | Positive | 34 (9.42) | 308 (22.42) | 85 (14.94) | ||
| Chemotherapy type | N (Col %) | Chemotherapy administered, type and number of agents not documented | 13 (3.52) | 113 (7.92) | 75 (12.86) | - |
| N (Col %) | Single-agent chemotherapy | 4 (1.08) | 586 (41.07) | 105 (17.77) | ||
| N (Col %) | Multiagent chemotherapy | 352 (95.39) | 728 (51.02) | 410 (69.37) | ||
| Surgery of primary site | N (Col %) | Unknown | 79 (21.41) | 406 (28.45) | 93 (15.74) | - |
| N (Col %) | Local tumor destruction, NOS | 0(0) | 1 (0.07) | 0(0) | ||
| N (Col %) | Photodynamic therapy | 0 (0) | 3 (0.21) | 2 (0.34) | ||
| N (Col %) | Electrocautery | 0 (0) | 6 (0.42) | 2 (0.34) | ||
| N (Col %) | Cryosurgery | 0 (0) | 1 (0.07) | 1 (0.17) | ||
| N (Col %) | Laser | 0 (0) | 1 (0.07) | 0(0) | ||
| N (Col %) | Local tumor excision, NOS | 1 (0.27) | 21 (1.47) | 3 (0.51) | ||
| N (Col %) | Laser ablation | 0 (0) | 0(0) | 1 (0.17) | ||
| N (Col %) | Laser excision | 0 (0) | 3 (0.21) | 1 (0.17) | ||
| N (Col %) | Polypectomy | 0 (0) | 11 (0.77) | 2 (0.34) | ||
| N (Col %) | Excisional biopsy | 1 (0.27) | 37 (2.59) | 12 (2.03) | ||
| N (Col %) | Gastrectomy, NOS (partial, subtotal, hemi-) | 15 (4.06) | 79 (5.54) | 39 (6.60) | ||
| N (Col %) | Upper (Proximal) gastrectomy | 20 (5.42) | 72 (5.05) | 43 (7.28) | ||
| N (Col %) | Near total or total gastrectomy | 43 (11.65) | 101 (7.08) | 60 (10.15) | ||
| N (Col %) | Gastrectomy, NOS with removal of a portion of esophagus | 48 (13.01) | 167 (11.7) | 80 (13.54) | ||
| N (Col %) | Partial or Subtotal gastrectomy with removal of a portion of esophagus | 75 (20.33) | 336 (23.55) | 164 (27.75) | ||
| N (Col %) | Near total or total gastrectomy with removal of a portion of esophagus | 40 (10.84) | 95 (6.66) | 39 (6.6) | ||
| N (Col %) | Gastrectomy, NOSb | 7 (1.9) | 15 (1.05) | 8 (1.35) | ||
| N (Col %) | Partial or subtotalb | 11 (2.98) | 35 (2.45) | 15 (2.54) | ||
| N (Col %) | Near total or total gastrectomyb | 26 (7.05) | 22 (1.54) | 17 (2.88) | ||
| N (Col %) | Radical gastrectomyb | 3 (0.81) | 15 (1.05) | 9 (1.52) | ||
Abbreviation: NOS, not otherwise specified.
a
The parametric p value is calculated by x2 test.
b
Gastrectomy resections with organs other than esophagus. Portions of esophagus may or may not be included in the resection.